Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Am Heart J. 2013 Jan;165(1):8-14. doi: 10.1016/j.ahj.2012.10.018. Epub 2012 Nov 20.
There is limited information about patterns of use of newer antithrombotic drugs in patients with acute coronary syndromes (ACS) in a real-life setting. The effectiveness, safety and cost-effectiveness of potential combinations during hospitalization, the duration of therapies, interruptions, or discontinuations as well as their reasons and possible consequences are unknown.
EPICOR (NCT01171404) is a prospective, multinational, observational study on patients discharged after a hospitalization for an ACS with 2-year follow-up. The study is designed to describe the patterns of antithrombotic use and to evaluate potential differences in short- and long-term clinical outcomes (ischemic and bleeding events), quality of life and economic impact associated with initial combinations during hospitalization, and treatment duration, discontinuations, or interruptions and their reasons after discharge in different clinical environments.
Between September 1, 2010, and March 31, 2011, 10,568 consecutive patients surviving an ACS (4943 with ST-segment elevation myocardial infarction, and 5625 with non-ST-segment elevation ACS) were enrolled from 555 hospitals in 20 countries from 4 pre-defined regions: Northern Europe (n = 3,782), Southern Europe (n = 2,337), Eastern Europe (n = 2,380), and Latin America (n = 2,069). Pre- and in-hospital management and outcomes were recorded, with a special focus on antithrombotic therapies and ischemic and bleeding events. Changes in antithrombotic treatments and outcomes are currently being registered during the planned 24-month follow-up.
EPICOR will show current patterns of antithrombotic use during hospitalization and after discharge in 'real-world' patients with ACS, allowing exploration of potential differences in clinical outcomes, quality of life, and costs related to the different antithrombotic practice patterns.
在现实环境中，关于急性冠脉综合征（ACS）患者使用新型抗血栓药物的模式信息有限。在住院期间，治疗方案的潜在组合的有效性、安全性和成本效益，治疗的持续时间、中断或停药及其原因和可能的后果均未知。
EPICOR（NCT01171404）是一项针对 ACS 住院后出院患者的前瞻性、多中心、观察性研究，随访时间为 2 年。该研究旨在描述抗血栓治疗模式，并评估住院期间初始治疗方案的潜在差异对短期和长期临床结局（缺血和出血事件）、生活质量和经济影响，以及出院后不同临床环境下的治疗持续时间、停药或中断及其原因。
2010 年 9 月 1 日至 2011 年 3 月 31 日，从 4 个预先确定的地区（北欧[ n = 3782]、南欧[ n = 2337]、东欧[ n = 2380]和拉丁美洲[ n = 2069]）的 555 家医院共连续入选了 10568 例存活的 ACS 患者（4943 例 ST 段抬高型心肌梗死，5625 例非 ST 段抬高型 ACS）。记录了患者的预住院和住院管理及结局，特别关注抗血栓治疗和缺血性及出血性事件。目前正在计划的 24 个月随访中登记抗血栓治疗方案的变化和结局。
EPICOR 将显示“真实世界”ACS 患者住院期间和出院后的抗血栓治疗模式，从而可以探索不同抗血栓治疗模式相关的临床结局、生活质量和成本的潜在差异。
